FDA approves first treatment for acute hepatic porphyria - Drug Information Update

FDA approves first treatment for adult patients with a rare genetic disorder known as acute hepatic porphyria

The U.S. Food and Drug Administration granted approval to Givlaari (givosiran) for the treatment of adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood). Common side effects for patients taking Givlaari were nausea and injection site reactions. Health care professionals are advised to monitor patients for anaphylactic (allergic) reaction and renal (kidney) function. Patients should have their liver function tested before and periodically during treatment. For more information, please visit: Givlaari.